Lena Shaghlil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lena Shaghlil has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Anas Alshishani
2 shared publications- Wan Sharuzi Wan Harun
Automotive Engineering Centre, Universiti Malaysia Pahang Al-Sultan Abdullah, Pekan, Malaysia
2 shared publications Yousef Al-Ebini
2 shared publications- Anas Alshishani
Faculty of Pharmacy, Zarqa University, Zarqa 13110, Jordan
1 shared publication Arunkumar Thirugnanasambandam
1 shared publicationAsmaa Abu Sa'ALeek
1 shared publication
Latest Publications
- Open Access
- 22 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 902
Advances in Intranasal CNS Targeting: Integrating Formulations, Devices, Computational Fluid Dynamics, and 3D Printing
Nose-to-brain (N2B) delivery is a practical, non-invasive strategy for CNS targeting that can increase brain exposure while limiting systemic exposure. This review integrates three milestones in N2B delivery, formulations, devices, and quantitative evaluation strategies, to define design rules for effective olfactory/trigeminal deposition and enhance translational relevance. Formulations emphasize mucoadhesive systems, nanoparticle carriers (polymeric, lipid-based, and hybrid), nano-emulsions, and stimuli-responsive “smart” gels that prolong nasal residence. Regarding device advancements, the review covers conventional nasal sprays optimized for plume geometry and droplet size. Furthermore, it examines breath-actuated metered sprays, which promote soft palate closure to route aerosols to superior regions, and vibrating mesh nebulizers capable of low-velocity mists for improved upper cavity deposition. Quantitative evaluation is discussed, including 3D-printed, anatomy-accurate nasal casts, high-speed spray diagnostics, and computational fluid dynamics (CFD). This review further links formulation and device parameters to regional deposition. Available clinical and animal data illustrate the feasibility of these approaches, safety considerations, and user-technique dependencies, while highlighting the need for standardized, anatomy-aware testing protocols. Together, these developments suggest that co-designed formulation device platforms, validated by cast/CFD metrics and supported by clinical imaging or pharmacokinetic data, can support N2B product development toward consistent, patient-relevant outcomes.
- 22 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 902
Open AccessAdvances in Intranasal CNS Targeting: Integrating Formulations, Devices, Computational Fluid Dynamics, and 3D Printing
Nose-to-brain (N2B) delivery is a practical, non-invasive strategy for CNS targeting that can increase brain exposure while limiting systemic exposure. This review integrates three milestones in N2B delivery, formulations, devices, and quantitative evaluation strategies, to define design rules for effective olfactory/trigeminal deposition and enhance translational relevance. Formulations emphasize mucoadhesive systems, nanoparticle carriers (polymeric, lipid-based, and hybrid), nano-emulsions, and stimuli-responsive “smart” gels that prolong nasal residence. Regarding device advancements, the review covers conventional nasal sprays optimized for plume geometry and droplet size. Furthermore, it examines breath-actuated metered sprays, which promote soft palate closure to route aerosols to superior regions, and vibrating mesh nebulizers capable of low-velocity mists for improved upper cavity deposition. Quantitative evaluation is discussed, including 3D-printed, anatomy-accurate nasal casts, high-speed spray diagnostics, and computational fluid dynamics (CFD). This review further links formulation and device parameters to regional deposition. Available clinical and animal data illustrate the feasibility of these approaches, safety considerations, and user-technique dependencies, while highlighting the need for standardized, anatomy-aware testing protocols. Together, these developments suggest that co-designed formulation device platforms, validated by cast/CFD metrics and supported by clinical imaging or pharmacokinetic data, can support N2B product development toward consistent, patient-relevant outcomes.
- 6 August 2025
- Published by Elsevier in Bioprinting
- Vol. 50
Material extrusion of biomaterials for transformative biomedical applications
- 6 August 2025
- Published by Elsevier in Bioprinting
- Vol. 50
Material extrusion of biomaterials for transformative biomedical applications
- Open Access
- 1 March 2023
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 13 (4) , 403-411
Solriamfetol impurities: Synthesis, characterization, and analytical method (UPLC-UV) validation
- 1 March 2023
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 13 (4) , 403-411
Open AccessSolriamfetol impurities: Synthesis, characterization, and analytical method (UPLC-UV) validation